FARMAKOEKONOMSKI ASPEKTI SHIZOFRENIJE
Sažetak
Shizofrenija je jedna od najtežih psihijatrijskih bolesti i spada u grupu neafektivnih psihoza. Karakteriše se poremećajima mišljenja, percepcije, emocija i ponašanja. Dvadeset četiri miliona ljudi širom sveta boluje od shizofrenije. Shizofrenija je hronična bolest povezana sa značajnim troškovima koje osim zdravstvenog sistema, snose šira društvena zajednica i porodica. Studije o troškovima lečenja shizofrenije sprovedene širom sveta pokazuju širok opseg sredstava koje zemlje izdvajaju iz ukupnog budžeta zdravstva za lečenje shizofrenije. Ona se kreću od 1.6 % do 2.5%. Međunarodne studije o troškovima lečenja shizofrenije zaključuju da su troškovi ove bolesti visoki, zavisni od zdravstvenog sistema i lokacije kao i da nematerijalni troškovi per se već opravdavaju ulaganja u ispitivanja i razvoj novih načina lečenja. Većina objavljenih radova sugeriše da atipični antipsihotici imaju bolji profil trošak-efikasnost od antipsihotika prve generacije. Smatra se da olanzapin, klozapin i risperidon imaju najpovoljniji profil trošak-efikasnost za lečenje shizofrenije.
Reference
Abi-Dargham A. Schizophrenia: overview and dopa-mine dysfunction. J Clin Psychiatry. 2014; 75(11):e31.
Piccinelli M, Gomez Homen F. Gender differences in the epidemiology of affective disorders and schizop-hrenia. Division of Mental Health and Prevention of substance abuse. Ed World Health Organization (WHO), Geneva; 1997.
Daltio CS, Mari JJ, Ferraz MB. Overview about pharmacoeconomics analysis and burden-of-illness in schizophrenia. Rev PsiquiatrClín. 2007; 34(2): 208-12.
Messias EL, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. PsychiatrClin North Am. 2007; 30(3): 323-38.
McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008; 30(): 67-76.
DegliEsposti L, Sangiorgi D, Mencacci C, Spina E, et al. Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study. BMC Psychiatry. 2014; 14:282.
Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004; 30(2): 279-93.
O’Malley AJ, Frank RG, Normand SL. Estimating cost-offsets of new medications: use of new antipsychotics and mental health costs for schizophrenia. Stat Med. 2011; 30(16): 1971-88.
Percudani M, Fattore G, Belloni GC, Gerzeli S, Contini A. Service utilisation and costs of first-contact patients in a community psychiatric service in Italy. Eur Psychiatry. 2002; 17(8): 434-42.
Lally J, MacCabe JH. Antipsychotic medication in schi-zophrenia: a review. British Medical Bulletin. 2015;114 (1): 169–79.
De Araújo AA, De AraújoDantas D, Do Nascimento GG, et al. Quality of Life in Patients with Schizophre-nia: The Impact of Socio-economic Factors and Adverse Effects of Atypical Antipsychotics Drugs.Psychiatr Q. 2014; 85: 357- 67.
Boyer L, Millier A, Perthame E, Aballea S, Auquier P, Toumi M. Quality of life is predictive of relapse in schizophrenia.BMC Psychiatry. 2013; 13:15.
Ayuso-Gutiérrez JL, del Río Vega JM. Factors influen-cing relapse in the long-term course of schizophrenia. Schizophr Res. 1997; 28(2-3): 199-206.
Emsley R,Chiliza B,AsmalL, Harvey BH. The nature of relapse in schizophrenia. BMC Psychiatry. 2013; 13:50.
Mangalore R, Knapp M. Cost of schizophrenia in England. J Ment Health Policy Econ. 2007; 10 (1): 23-41.
Goeree R, Farahati F, Burke N, Blackhouse G, O’Reilly D, Pyne J, Tarride JE. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005; 21(12): 2017- 28.
Carr VJ, Neil AL, Halpin SA, Holmes S, Lewin TJ. Costs of schizophrenia and other psychoses in urban Australia: findings from the Low prevalence (psychotic) disorders study. Aust N Z J Psychiatry. 2003; 37(1): 31-40.
Cloutier M, AigbogunMS, Guerin A, Nitulescu R, Ramanakumar AV. The Economic Burden of Schizop-hrenia in the United States in 2013. The Journal of Cli-nical Psychiatry. 2016; 77(6): 764-71.
Cocchi A, Mapelli V, Meneghelli A, et al. Cost-effec-tiveness of treating first-episode psychosis: five-year follow-up results from an Italian early intervention programme. Early Interv Psychiatry. 2011; 5(3): 203-11.
Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res. 2011; 3: 9-14.
American Psychiatric Association. Diagnostic and Stati-stical Manual of Mental Disorders fifth edition (DSM-5). Washington: American Psychiatric Association, 2013.
Stroup TS, Lieberman JA, McEvoy JP, et al. Effective-ness of olanzapine, quetiapine, risperidone, and zipra-sidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006; 163(4): 611-22.
National Institute for Health and Care Excellence. Psychosis and schizophrenia in adults: treatment and management; 2014.https://www.nice.org.uk/guidance/cg178/evi-dence/full-guideline-490503565((accessed December 31, 2017).)
O’Day K, Rajagopalan K, Meyer K, Pikalov A, Loebel A. Long-term costeffectiveness of atypical antipsychotics in the treatment of adults with schi-zophrenia in the US. Clinicoecon Outcomes Res. 2013;5:459-70.
Jones PB, Barnes TR, Davies L, et al. Randomized con-trolled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia. Arch Gen Psychiatry. 2006; 63(10): 1079-87.
Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. The Lancet. 2013; 382: 951- 62.
Liu-Seifert H, Ascher-Svanum H, Osuntokun O, Jen KY, Gomez JC. Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics. BMC Psychiatry. 2011; 11: 87.
McEvoy JP. The costs of schizophrenia. J Clin Psychiatry. 2007; 68(14): 4-7.
Lay B, Nordt C, Rössler W. Trends in psychiatric hospitalisation of people with schizophrenia: a register-based investigation over the last three decades. Schi-zophr Res. 2007; 97(1-3): 68-78.
Ou JJ, Xu Y, Chen HH, et al. Comparison of metabolic effects of ziprasidone versus olanzapine treatment in patients with firstepisode schizophrenia. Psychopharmacology (Berl). 2013; 225(3): 627-35.
Zhang S, Lan G. Prospective 8-week trial on the effect of olanzapine, quetiapine, and aripiprazole on blood glucose and lipids among individuals with first-onset schizophrenia. Shanghai Arch Psychiatry. 2014;26(6): 339-46.
Santos AS, Vidal CEL, Brandão CMR. Cost-effective-ness of atypical antipsychotics for the treatment of schizophrenia. J Bras Econ Saúde. 2016; 8(3): 204-15.
Davies LM, Lewis S, Jones PB, et al. Cost-effective-ness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizop-hrenia responding poorly to previous therapy. The Bri-tish Journal of Psychiatry. 2007; 191(1): 14-22.
Davies L, Lewis S. Antipsychotic Medication for Peo-ple with Schizophrenia: An Exploratory Economic Analysis of Alternative Treatment Algorithms. 2000; Discussion Paper 178. University of York, Centre for Health Economics.
Bagnall AM, Jones L, Ginnelly L, et al. A systematic review of atypical antipsychotic drugs in schizophre-nia.Health Technol Assess. 2003; 7(13).
Santos AS, GodóiIP ,Vidal CEL, Ruas CM. Economic evaluation of antipsychotics for the treatment of schi-zophrenia: a systematic review. J Bras Econ Saúde. 2017; 9(2): 207-28.
Taylor D, Knapp M, Kerwin R. Pharmacoeconomics in psychiatry. London: Martin Dunitz, 2002.
Autori zadržavaju autorska prava i pružaju časopisu pravo prvog objavljivanja rada i licenciraju ga Creative Commons licencom koja omogućava drugima da dele rad uz uslov navođenja autorstva i izvornog objavljivanja u ovom časopisu.
Autori mogu izraditi zasebne, ugovorne aranžmane za neekskluzivnu distribuciju rada objavljenog u časopisu (npr. postavljanje u institucionalni repozitorijum ili objavljivanje u knjizi), uz navođenje da je rad izvorno objavljen u ovom časopisu.
Autorima je dozvoljeno i podstiču se da postave objavljeni rad onlajn (npr. u institucionalnom repozitorijumu ili na svojim internet stranicama) pre i tokom postupka prijave priloga, s obzirom da takav postupak može voditi produktivnoj razmeni ideja i ranijoj i većoj citiranosti objavljenog rada (up. Efekat otvorenog pristupa).